The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of prostate carcinoma

Prostate cancer is the most commonly diagnosed malignancy and second leading cause of cancer death among men in the United States. In recent years, several new agents, including cancer immunotherapies, have been approved or are currently being investigated in late-stage clinical trials for the manag...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Immunother Cancer
Main Authors: McNeel, Douglas G., Bander, Neil H., Beer, Tomasz M., Drake, Charles G., Fong, Lawrence, Harrelson, Stacey, Kantoff, Philip W., Madan, Ravi A., Oh, William K., Peace, David J., Petrylak, Daniel P., Porterfield, Hank, Sartor, Oliver, Shore, Neal D., Slovin, Susan F., Stein, Mark N., Vieweg, Johannes, Gulley, James L.
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2016
Assuntos:
Position Article and Guidelines
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5170901/
https://ncbi.nlm.nih.gov/pubmed/28031820
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40425-016-0198-x
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados